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Introduction
The genus Trypanosoma consists of flagellated protozoa parasites that cause infections in
humans and animals. The most relevant infectious diseases to humans are African trypanosomiasis
and Chagas disease caused by Trypanosoma brucei, Trypanosoma cruzi, respectively, which are
considered as neglected tropical diseases (NTDs) [1]. Most affected by these parasitic diseases are
low-income populations of countries located in tropical and subtropical areas of the world.
CHAGAS DISEASE
Chagas disease (ChD) or American Trypanosomiasis is caused by the protozoan parasite
Trypanosoma cruzi. The parasite has a complex life cycle, which alternates between triatomine
vectors and mammals, including humans. The disease can cause cardiac disorders, digestive or
neurological alterations. T. cruzi is genetically diverse; it has been classified in six discrete typing
units (DTU)s: TcI, TcII, TcIII, TcIV, TcV, and TcVI, which present different antigenicity, ecoepidemiological, clinical, and geographic associations [2]. It is considered a neglected tropical
disease with endemic regions located in 21 Latin American countries, where it is mostly vectorborne when humans come across the feces or urine of the infected triatomine bug [3, 4].
Epidemiology
According to the World Health Organization (WHO), about 6 to 7 million people
worldwide are estimated to be infected with ChD. Over the past half of the 20th century, there has
been an increased migration of Latin Americans to non-endemic countries, greatly modifying the
epidemiology of the disease. In the last decades, it has been detected in the U.S and Canada. Even
in the Old World, T. cruzi has been detected in countries such as Japan, Australia and most of the
European continent, where an approximate large number of immigrants infected with the
protozoan live in Spain and Italy [3, 5]. Solely looking at the U.S., there are an estimated 300,000
1

infected individuals with T. cruzi in the states of New Mexico, Texas, Georgia, Louisiana and
California [6, 7]. It is estimated that most individuals with ChD are immigrants that came from El
Salvador, Guatemala, Honduras, and Mexico that acquired the infection in their countries of birth;
the last accounting for around 174,388 infected individuals living in the U.S. [8-10]
Mexico is a country with immense climatic variety and vast biodiversity, providing the
conditions for the development of etiological agents of all kinds, including T. cruzi. There are at
least 30 species of triatomines reported in the country, all known to be potential vectors [11]. ChD
remains as the most important parasitic disease in the country. As of 2010, it was estimated that
876,458 people was infected with T. cruzi and 70,117 people had chagasic cardiopathy [12]. The
poverty in the country has forced people from endemic areas of the country to migrate to
industrialized cities like Mexico City, in search of jobs. Carabarin-Lima et. al. report that the
children under 5 years of age infected with ChD are distributed regularly in urban rather than rural
areas, suggesting that ChD is becoming urbanized in Mexico [13].
In Mexico, there are 18 endemic areas located in the southeast comprising the states of
Oaxaca, Jalisco, Yucatan, Chiapas, Veracruz, Puebla, Guerrero, Hidalgo and Morelos. A high
prevalence is observed in the northeastern region of the country, which corresponds to the central
area of a tropical region known as La Huasteca [13]. But the highest prevalence (1.94% - 1.68%)
was observed in the US neighbor states of Nuevo Leon and Tamaulipas [13, 14].
In the southeast of the state of Chihuahua, near the limits of the states of Sonora and Sinaloa
there is an area known as Barrancas de la Sierra Tarahumara, where there have been reports of
triatomines infected with T. cruzi. In a study conducted by the Immunoparasitology Laboratory of
the Medical School at the Autonomous University of Chihuahua, a sample of Triatoma recurva
collected in the Chihuahuan municipality of Urique was found to be infected with T. cruzi [15].
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Licon-Trillo et. al. (2007) conducted a study where they collected triatomine bugs for nearly one
month from the municipalities of Ojinaga and Benavides in the state of Chihuahua. The results
were 11 triatomine bugs collected (T. gerstaeckeri and T. rubida) with one of them being infected
with T. cruzi [16].
Several species of triatomine insects have been reported in states bordering the southern
United States with infections rates ranging from 0% to >90% [14]. A recent study conducted near
Van Horn, Texas at The University of Texas at El Paso Indio Mountains Research Station has
confirmed that 64.1% of the triatomines tested were infected with T. cruzi strains belonging to the
DTU TcI [17].
Life cycle
The triatomine insect serves as the vector for T. cruzi, it ingests circulating trypomastigotes
when it takes a blood meal from an infected host. The parasite transforms into epimastigote, which
is the replicative stage, inside the midgut of the insect. Epimastigotes travel to the hindgut and
differentiate into infective metacyclic trypomastigotes and are excreted in the feces of the vector.
Metacyclic trypomastigotes enter through the bite wound or mucous membrane of the host and
invade nucleated cells through a parasitophorous vacuole. The parasite escapes the from the
lysosome vacuole; in the cytoplasm, it differentiates into the replicative form called amastigote.
After several rounds of binary division, the amastigotes transform into trypomastigotes and burst
out of the host cell. The trypomastigotes released into the blood stream can infect new cells and
the cycle is repeated [6].
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Figure 1. The life cycle of Trypanosoma cruzi. 1. Triatomine bug takes a blood meal releasing
metacyclic trypomastigotes in the feces. 2. Metacyclic trypomastigoes enter the bite
wound or mucosal membranes infecting nucleated cells. 3. Inside nucleated cells,
the parasite transform into amastigotes and multiply by binary fission. 4.
Amastigotes transform into trypomastigotes and burst out of the cell to infect new
cells. 5. A triatomine bug takes a blood meal from infected mammalian host
ingesting trypomastigotes. 6. Trypomastigotes transform into epimastigotes in the
midgut. 7. Epimastigotes replicate by binary fission. 8. Epimastigotes travel to the
hindgut where they transform into metacyclic trypomastigotes to be released in
feces. (from Center for Disease Control and Prevention, 2015) [18]
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Pathogenesis
T. cruzi is a hemoflagellate protozoan that can infect all nucleated cells: macrophages,
fibroblasts, nerve cells, and muscle cells [19]. Infection with T. cruzi presents two clinical
manifestations: the acute phase characterized by manifestations of generalized infection like fever
followed by the chronic phase that can be divided into indeterminate, cardiac or, digestive form
[20]. The acute phase it is characterized by trypomastigotes detectable by microscopy of fresh
blood. Although patients are mostly asymptomatic, some develop swelling and inflammation at
the site of infection, which is known as chagoma [6]. Tissue and organ damage is caused by both
the parasite and the host’s immune response. Several studies have suggested that a strong immune
response with CD4+ and CD8+ cells and production of cytokines such as interferon γ, tumor
necrosis factor α, and interleukin 12 are important in controlling parasitism [5].
In the absence of treatment, the individual enters the chronic phase, which can be
asymptomatic, or it can lead to premature death. Up to 30% of individuals in the chronic stage
develop cardiac alterations and up to 10% develop digestive, neurologic or a combination of
alterations which require specific treatment [3]. Most patients that proceed to the chronic phase do
not exhibit clinical disease despite presenting positive serology, abundant antibody production and
a robust T cell response to parasite and host antigens [21]. These patients are in the indeterminate
phase since they can carry the parasite for years and their life expectancy is comparable with
individuals without ChD [20]. Studies in indeterminate patients have shown that they produce
inflammatory cytokines such as TNF-α and IFN-γ. While regulatory T cells, monocytes and
lymphocytes produce anti-inflammatory cytokines, especially IL-10. Most notably, in
indeterminate patients the balance between inflammatory and anti-inflammatory cytokines leans
towards the anti-inflammatory arm of the response [21].
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Digestive ChD is seen mostly in the South of the Amazon basin, and rare in northern South
America, Central America and Mexico and affects the esophagus and/or colon caused by the
destruction of intramural neurons leading to severe megaesophagus or megacolon [5, 6].
According to Rassi et. al. (2010) megaoesophagus causes dysphagia with odynophagia, epigastric
pain, regurgitation and in severe cases, malnutrition [5]. And megacolon often affects the sigmoid
segment, rectum or descending colon, or a combination, and produces prolonged obstipation due
to fecaloma or sigmoid volvulus [5].
Cardiac ChD is characterized by chronic inflammation of all chambers of the heart, damage
to the conduction system and often an apical aneurism, bradyarrhythmia, tachyarrhythmia, cardiac
failure, thromboembolism and sudden death [5, 6]. Dutra et. at. (2014) observes that, contrary to
patients in the indeterminate phase, cardiac ChD present a predominance of inflammatory
cytokines [21]. The author also mentions studies where, regardless of IL-10 production in cardiac
patients, TNF-α producing cells were predominant in the damaged tissue. Additionally, T-cells in
heart tissue from an infected individual displayed predominant expression of IFN-γ over other
cytokines [21]. Dutra et. al. (2014) reported that the production of TNF-α and IFN-γ has been
associated with clinical signs of cardiac pathology. Individuals with higher TNF-α production
showed worse cardiac function and a worse prognosis of disease progression. In addition, a study
displayed that patients with high production of IFN-γ presented a worse degree of cardiomyopathy
[21].
Status in Mexico
Chagas disease has been largely considered neglected in Mexico. Blood screening of
donors for T. cruzi was mandated in certain Latin America countries in 1990. But in Mexico, it
was until 1994 when legislation was passed suggesting that donors who resided in endemic areas

6

should be tested serologically, but at that time no endemic areas defined by that legislation [22,
23]. ChD came to the government’s attention again in 2000, when it passed new legislation
mandating serological screening of blood donors, and later the Mexican Initiative for Surveillance
and Control of Chagas Disease was convened in 2002 [24].
Despite the directive from the Ministry of Health to test donated blood, even in areas that
self-identified as endemic, diagnostic testing is not being carried out in all blood banks. And one
of the reasons is resource shortages, which is responsible for only 30% of the national blood supply
being processed through initial screening and follow-up testing to confirm diagnosis [22, 24]. The
health sector reports any cases and deaths due to ChD to the National Center for the Prevention
and Control of Diseases, with most of the cases being reported by the Secretary of Health [25].
Although one problem remains in the current reporting system, and that is that it does not
distinguish among acute, indeterminate and chronic phases of the disease. Even with
implementation of surveillance methods, ChD continues to be understudied and poorly controlled
in Mexico [24].
Health care and clinical personnel have deficient knowledge regarding ChD, its
transmission, diagnosis or treatment due to neglect by healthcare system policies. Most individuals
with ChD are asymptomatic or symptomatic without clinical manifestations, and the health care
personnel are unaware of the potential risk in blood transfusions. In 2010, Trivedi M. and Sanghavi
D. performed a study across 9 blood banks in Mexico City, where a total of 45 nurses who screen
donors were given a survey to measure their knowledge about ChD. Their results showed that out
of the three questions, 80% of nurses answered one question incorrectly or incompletely, and 13%
had two incomplete or incorrect answers [22, 26]. Even the general population lacks an
understanding of the disease. For example, in an endemic area such as state of Morelos, about 45%
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of the general population is aware of the triatomine vectors, but only about 15% have an
understanding of the disease, its clinical manifestations and how to prevent and treat it. This is
mainly because is the responsibility of the state Secretaries of Health to implement education
programs; as such there is serious heterogeneity in these programs in different states [25].
Contributing to the problem is the fact that there are no standard procedures for the
isolation, study and keeping of T. cruzi strains in a “national” bank of stains. This could benefit
research for the origin, virulence or other characteristics of the Mexican strains of T. cruzi, and
possibly aid in the improvement of better diagnostic tools [11].
Another problem in Mexico is in regard to the treatment of confirmed cases of ChD. There
are three major insurance schemes responsible for the access of treatment for ChD, the Mexican
Social Security Institute (IMSS), Institute for Social Security and Services for State Workers
(ISSSTE) and Seguro Popular (SP). These institutions diagnose patients and report confirmed
cases to the State Secretaries of Health, who in turn report the cases to the national Program on
Onchocerciasis, Leishmaniasis and Chagas Disease to provide the medicines to begin treatment of
the disease [25]. As reported by Manne J. M., since 2009 the national program has requested
nifurtimox from the WHO-Bayer Nifurtimox Donation Program to offer medicines for registered
cases by the state Secretaries of Health, who then are in charge of the distribution to begin
treatment. The only exception was the state of Morelos, where its state Program on Chagas Disease
chose to purchase benznidazole directly from Masters Pharmaceutical, Ltd. in 2010. The Mexican
Secretary of Health established guidelines that were updated in 2010 stating that nifurtimox is the
first-line antitrypanosomal therapy in patients who have either acute or indeterminate ChD, even
when benznidazole is widely considered the first-line treatment on basis of a better side-effect
profile and a more extensive evidence base for efficacy [25, 27, 28].
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Researchers have long recognized that studies in Mexico suffer from several limitations.
Amongst those, they have reported that utilizing the official national surveillance data is difficult
to interpret and can lead to a large underestimation of disease burden [24]. Data on prevalence of
ChD is also reported to be limited both in Mexico and globally. Furthermore, underreporting is a
serious issue because ChD has few acutely symptomatic cases and there is a limited pool of clinical
experts in the country [25, 29].
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Chapter 1: Multi-antigen Chemiluminescent-ELISA for diagnosis of T. cruzi
infection.
The diagnosis of ChD has undergone great progress with the development and
commercialization of assays based on different T. cruzi antigens. In recent years, utilizing
recombinant antigen mixtures have shown better specificity, but their actual sensitivities were
somewhat lower [30]. During the chronic stage, parasitemia is low and immunodiagnosis is the
appropriate technique to determine the presence of T. cruzi. A diagnosis is made after testing with
at least two serologic tests: indirect fluorescent antibody (IFA) and commercial enzyme-linked
immunosorbent assay (ELISA) [31]. PCR is a useful tool when trying to confirm the diagnosis of
inconclusive serology and as an auxiliary method in tracking treatment progression [5]. In Mexico,
the Mexican Social Security Institute (IMSS) utilizes a wide variety of companies to provide
serological tests for the diagnosis of ChD [32]. This lack of consistency within the assays and the
lack of a gold standard test might contribute to unreliable reporting of the disease.
As mentioned previously, T. cruzi has been classified in several DTUs, and yet, the
correlations between DTUs, geographical distribution, host species and pathogenicity remain
controversial. It was considered that DTUs TcII, TcV, and TcVI were related to human infections
and TcI, TcIII, and TcIV were related to the sylvatic cycle. However, reports in Colombia and
Venezuela revealed that human infections were caused by TcI, TcIII, and TcIV [33]. The genetic
variability in T. cruzi strains alters diagnostic results widely when testing sera from patients
infected with parasites from different geographical regions or with different DTUs. This has led to
the recommendation of favoring local strains to ensure the specificity and sensitivity of the test
[30].
Serological tests using synthetic peptides have shown promising results. The combination
of three T. cruzi recombinant proteins in an ELISA culminated in a test that is sensitive and specific
10

for the diagnosis of ChD [34]. Almeida I. C. et. al. (1997) developed a highly sensitive and highly
specific chemiluminescent ELISA (CL-ELISA), that due to its increased sensitivity allows for the
usage of a higher dilution of sera (1:2000), eliminating most indeterminate or inconclusive results
[35]. He emphasizes the low sensitivity of current methodologies using low dilutions of human
sera increasing background reactivity of natural antibodies. Also, the increase in low tittered
polyclonal antibodies induced by various immunogens, such as anti-bacterial vaccines, can result
in false-positives [35]. Previous studies have concluded that the combination of epidemiological
data and high-performance testing can result in a more precise view on the status of donors [36].
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HYPOTHESIS
We hypothesize that a multiantigen chemiluminescent-ELISA comprised of DTUs TcI,
TcII and TcVI will detect the presence of anti-T. cruzi antibodies with higher sensitivity in sera
samples from Mexico.

SPECIFIC AIM
Develop a chemiluminescent multiantigen ELISA assay using T. cruzi epimastigotes of
five strains for detection of anti-T. cruzi antibodies.
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MATERIALS AND METHODS
Epimastigote culture
T. cruzi epimastigote strains endemic in South America (Dm28c, Y-strain, and CL-Brener)
and strains endemic in the Southern United States (Texas-Tulane and Houston) were obtained from
the American Type Culture Collection (ATCC) (American Type Culture Collection, Manassas,
VA, USA). Parasites were cultivated in 1L Liver Infusion Tryptose (LIT) medium supplemented
with 10% inactivated fetal bovine serum (Corning Inc. Corning, NY, USA) and 1%
penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) [37] for 6 days and
incubated at 27°C.
Antigen preparation
The epimastigote multiantigen (EpM) was prepared using epimastigotes of five T. cruzi
strains: Dm28c, Y-strain, CL-Brener, Texas-Tulane and Houston as previously described by
Almeida et. al. (1997) with minor modifications [35]. Parasites were collected the sixth day after
the last passage, centrifuged at 1000 xg for 15 minutes at 4°C, and washed three times in 1 X
phosphate buffer saline (pH 7.4). The parasites pellet was resuspended in Tris-HCl 10 mM (pH
7.4) (Fisher Scientific, Hampton, NH, USA), EDTA 2mM (Fisher Scientific, Hampton, NH, USA),
protease inhibitor cocktail EDTA-free (dilution 1:10) (Thermo Fisher Scientific, Waltham, MA,
USA), and 1% nonanoyl-N-methylglucamide (Sigma-Aldrich, St, Louis, MO, USA). The
suspension was then submitted to six cycles of freezing and thawing in liquid nitrogen and water
bath at 37°C. Followed by sonication (35% amplitude for 8 seconds, five times) (VCX 750, Sonics
& Materials Inc., Newton, CT, USA). The lysate suspension was centrifuged at 12,000 xg for 10
minutes at 4°C. Protein concentration was determined by the Bradford assay (Thermo Fisher
Scientific, Waltham, MA, USA), and equal quantities of each (407 µg) were used to produce the
EpM.
13

Sample collection
This experiment was approved by The University of Texas at El Paso Institutional Review
Board, and performed under the IRBnet Exempt protocol [267936] Chagas disease screening in
samples from State Blood Bank of Transfusion, Chihuahua-Mexico. All shipping in Mexico was
done via a commercial courier with expertise in the transport of blood and blood components.
Upon arrival to Ciudad Juarez, Mexico, the CDC transported the samples through the border to El
Paso, Texas. It is important to highlight that Dr. Maldonado never had access to the patients’
personal information.
As per Mexican law, all donors were between 18 and 65 years of age and weight at least
110 pounds (50 kg). Donors agreed to participate in the study by signing a consent form provided
by the Pan American Health Organization (PAHO). Aliquots collected were maintained at the
constant recommended temperature of -80C during storage and throughout the shipping process.
To minimize the frequency of shipping samples over the border during the period of study, samples
were collected first throughout the State of Chihuahua and sent to the CETS in Chihuahua. Then,
the CETS kept one aliquot and sent the other two to the University of Chihuahua in Chihuahua
City (UACH) and to Ciudad Juárez, either once a month or when they were at least 100 samples
collected, whichever was reached first. The one aliquot sent to UTEP (The University of Texas at
El Paso), was used for examination with the CL-ELISA. If the donor is confirmed positive for
Chagas disease the Mexican authorities will contact the donor to provide medical attention and
follow up.
Sera
Serum samples were collected from the blood banks of the Mexican Social Security
Institute (IMSS) No. 1, No. 35 and No. 66, the State Blood Transfusion Center (CETS) in
Chihuahua City, and blood banks from the City of Juarez Hospital, Parral City General Hospital,
14

Delicias City Hospital and Cuauhtémoc City Hospital (Table 1). After the subjects have donated
blood, each blood bank performed the routine screening for infectious agents (e.g. HIV, Syphilis,
hepatitis C, etc), as well as the approved procedure for detection of ChD as outlined in Mexican
norm NOM-032-SSA2-2002. The reactive sera were tagged and 4 aliquots of 1ml were frozen
with glycerol, if non-reactive, one percent of samples were retained at random. The samples
included in the study were assigned a coded serial number to protect the identity of the subjects
and to facilitate operational research design. This serial number will be matched to correspond to
a file at the blood donation center where the sample was originated from. Through this number,
the following information is available: name of the donor, donation site, date and time of sampling
procedure, and contact information (all registered as a bar code).
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Table 1. Flow chart of the procedures that were followed for the collection, handling and
analysis of the donors’ samples.
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Chemiluminescent Enzyme-Linked Immunosorbent Assay (CL-ELISA)
EpM antigens were diluted in carbonate-bicarbonate buffer (pH 9.6) and immobilized on
96-well white polystyrene microplates (Nunc, Thermo Fisher Scientific, Waltham, MA, USA), by
incubating 24 hr at 4°C. The plates were blocked with 5% bovine serum albumin in 1X phosphate
buffered saline pH 7.4 (5% BSA-PBS). Followed by 1 h incubation with the patient sera diluted
1:500 in 1% BSA-PBS at 37°C. Plates were washed three times with PBS-Tween 0.05% (PBS-T)
and then incubated for 1 h at 37°C with 50µl of anti-human IgG biotinylated (GE Healthcare, Little
Chalfont, Buckinghamshire, United Kingdom) diluted 1:5000 in 1% BSA-PBS. Next, plates were
washed three times with PBS-T, followed by 1 h incubation at 37°C with 50µl of neutravidinhorseradish peroxidase (Thermo Fisher Scientific, Waltham, MA, USA) diluted 1:5000 in 1%
BSA-PBS, then washed 4 times with PBS-T. Finally, 50µl of Supersignal ELISA Pico Stable
Peroxide Solution, Supersignal ELISA Pico Luminol Enhancer (Thermo Fisher Scientific,
Waltham, MA, USA) diluted in carbonate-bicarbonate buffer at a ratio of 1:1:8 were added to each
well and the data was analyzed utilizing a microplate luminometer (Luminoskan, Thermo Fisher
Scientific, Waltham, MA, USA). Each plate included a positive control (pool of Chagasic patients
from Barcelona, Spain), a negative control (pool of healthy donors from Barcelona, Spain) and a
background control (incubations done with no sera added). The assay was performed in duplicates,
and both mean and standard deviation where calculated using GraphPad Prims v6.0. Positive and
negative controls were pools of sera comprised of 10 patients with ChD and 10 healthy donors,
respectively (kindly provided by Dr. I. C. Almeida, UTEP).
Cutoff value for the EpM CL-ELISA was calculated by first determining the reactivities,
reported as relative light units (RLU), of the 10 healthy donor sera that comprised the pool used in
the assay. The mean and the standard deviation of these reactivities were calculated. A value of 3
times the standard deviation was added to the mean for the cutoff value. The titer of the EpM CL17

ELISA is defined as the ratio of the serum’s RLU to the cutoff value (titer = RLU/cutoff value). A
serum sample with a titer equal or greater than 1.0 was considered positive. A serum sample that
presented a titer lower than 0.9 was considered negative. And any serum sample with a titer in the
range of 0.9 to 0.99 was considered as inconclusive.
RESULTS
Chemiluminescent Enzyme-Linked Immunosorbent Assay (CL-ELISA)
Several titrations were performed utilizing multiantigen concentrations ranging from a low 4
ng/well to a high concentration of 120 ng/well. Control sera were serially diluted pools (1:2) of
Chagasic patients’ sera and healthy donors from 1:250 to 1:2000. Titrations were performed in to
determine the ideal concentration of antigen and sera dilution that would present a significant
separation in the reactivities between both controls. We analyzed the results and determined that
the greatest differential reactivity between control sera was observed at a 1:500 sera dilution and
an EpM antigen concentration of 108 ng/ml (Fig. 2).
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Figure 2. Titration curves for the EpM CL-ELISA. Sera were serially diluted (1:2) from 1:250 to
1:2000 in 1% BSA-PBS. (A) EpM CL-ELISA multiantigen at 4 ng/well. (B) EpM
CL-ELISA multiantigen at 10 ng/well. (C) EpM CL-ELISA multiantigen at 40
ng/well. (D) EpM CL-ELISA multiantigen at 108 ng/well. (E) EpM CL-ELISA
multiantigen at 120 ng/well. Positive control: pool of 10 Chagasic patients from
Barcelona, -●-; negative control: pool of 10 healthy donors from Barcelona, -■-;
serum sample of a known healthy donor -▲-. The highest differential reactivity
between positive and negative sera was determined at (D) multiantigen
concentration of 108 ng/well and sera dilution of 1:500. Titrations were performed
in triplicates and the results represent the means of the replicates.
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The sera samples were previously tested in Mexico utilizing the automated
Chemiluminescent Microparticle Immunoassay (CMIA) with ARCHITECT® (Abbott, Chicago,
IL, USA); reactive samples were later tested with serology, either IIF IHA or ELISA according to
NOM-032-SSA2-2002, to confirm previous results. Concluding the second methodology, there
were 54 samples that were deemed inconclusive. Using this multiantigen CL-ELISA (EpM CLELISA) as a reference, out of the 319 sera samples analyzed, 13 (4.1%) were positive and 306
(95.9%) were negative without any inconclusive samples (Fig. 3).
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Figure 3. Reactivity of EpM CL-ELISA using the multiantigen of T. cruzi epimastigotes
(108ng/well). Donor samples (n=319) were diluted 1:500 in 1% BSA-PBS and
tested in duplicates. Individual sera comprising the pools of Chagasic patients
(n=10) and healthy donors (n=10) respectively, were diluted 1:500 in 1% BSA-PBS
and assayed in triplicates to determine the cutoff value. Dotted line, a cutoff value
corresponding to titer = 1.0. A sample is considered positive when its titer is equal
to or higher than 1.0 and negative when its titer is less than 0.9. Samples with titers
ranging from 0.9-0.99 are considered as inconclusive. The reported results represent
the means of the replicates.
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Statistical analysis
The means and standard deviations were calculated utilizing GraphPad Prism 6, and the
cutoff was established as the mean plus three times the standard deviation of the NHS (negative
control). To assess the reproducibility of the assay, estimates of inter-assay and intra-assay for
both controls were calculated in accordance with the methods previously described [38, 39]. The
coefficients of variability (CV) for repeated assays was lower than 10 percent in all cases (Table
2); which indicates a good reproducibility of the assay.
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Table 2. Reproducibility of the EpM CL-ELISA
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DISCUSSION
The protozoan parasite T. cruzi is the causative agent of Chagas disease; a neglected
tropical disease affecting about 6 to 7 million people estimated to be infected with the parasite [3].
In the U.S., there are an estimated 300,000 infected individuals, with several reports of people
infected with T. cruzi in the states of New Mexico, Texas, Georgia, Louisiana and California [6,
7]. In Mexico, the states of Tamaulipas and Coahuila have reported as endemic areas, this is
important because those states are bordering with Texas [13, 14].
Based on the different characteristics of the different DTUs, we prepared the multiantigen
with five T. cruzi strains to improve the specificity and sensitivity of the ELISA assay. T. cruzi
Dm28c is classified as TcI [40], which is the most widely dispersed DTU in the American
continent covering South, Central, and North America and is associated with both domestic and
sylvatic cycles [41]. T. cruzi Y-strain corresponds to DTU TcII [40], which can be found in the
south and central regions of South America and occasionally further north. It has been isolated
mostly from domestic cycles [41]. T. cruzi CL Brener strain is classified in lineage TcVI [40];
together with lineage TcV both are hybrids associated with ChD in southern and central South
America and are known mostly as domestic isolates [41]. Zingales et al. stated that the lineages
TcI and TcIV are found in the Southern United States; both T. cruzi Houston and Texas-Tulane
strains were found in the state of Texas [42, 43] and have been classified as TcI (Ramirez, Orozco
and Maldonado, unpublished).
The chronic stage of the disease is when parasitemia is low and serological tests are the
most suited option for the diagnosis of the disease [5]. A study by Umezawa et. al. (2003) has
shown promising results when several T. cruzi recombinant proteins are included in a single
ELISA [44]. Pereira et. al. (2012) reported that the combination of high performing testing along
with epidemiological data can improve diagnostic capabilities [36]. Previously, Almeida et al
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(1997) developed a CL-ELISA highly specific, able to confirm the cure of treated patients after
two years of treatment [35]. Following these ideas, we developed the multiantigen of T. cruzi
epimastigotes by selecting strains classified in different DTUs across the American continent to
use in combination with a CL-ELISA. In our experiment, the EpM CL-ELISA analyzed 319 sera
samples and concluded with 13 (4.1%) positive samples and 306 (95.9%) negative samples without
any inconclusive. From the 13 seropositive samples in our EpM CL-ELISA, the conventional
serological tests previously diagnosed 3 sera as inconclusive, 5 as positive and another 5 as
negative. The results of this assay indicate that the EpM CL-ELISA is highly sensitive for the
diagnosis of ChD compared to conventional serological tests.
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Chapter 2: Immunoblot of seropositive samples to assess performance of EpM
CL-ELISA as a diagnostic tool.
T. cruzi displays on its surface numerous glycoconjugates that are involved in the
recognition and invasion of mammalian host cells, as well as establishing and sustaining the
chronic infection of ChD [45]. Its genome is at least 50% repetitive sequence, consisting of large
gene families of surface proteins, retrotransposons and subtelomeric repeats. The largest gene
families encode surface proteins such as mucin-associated surface proteins (MASPs), members of
the trans-sialidase (TS) super family, mucins and the surface glycoprotein gp63 protease, all
accounting for ~18% of the total protein-coding genes [46]. Acting at the interface between the
parasite and the vector or the mammalian host, these molecules are suited to fulfill two purposes:
provide protection against the vector and/or host's defense mechanisms and to ensure the targeting
and invasion of specific cells or tissues [47].
The surface of the different stages of T. cruzi is covered by a thick coat of glycoconjugates.
The major component is a family of mucin-like proteins, which are glycoconjugates highly
glycosylated rich in Thr, Ser and Pro that serve as acceptor sites for the addition of O-linked
oligosaccharides. Their core polypeptides are only 50-200 amino acids in length and are anchored
to the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor [47-49]. The deduced
polypeptide sequences of the native mucin polypeptide chain can be divided in two families.
Family I polypeptides are composed of central domain rich in Thr, Lys and Pro organized in blocks
with the repetitive motif (Thr)8Lys(Pro)2. These blocks are flanked by a highly variable and short
N-terminal region and a more conserved C-terminal region. In Family II polypeptides, they too
show N- and C-terminal regions similar to Family I polypeptides, but their Thr concentration is
much lower and they lack the repetitive motif (Thr)8Lys(Pro)2. It has been observed that Family I
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sequences are expressed in epimastigotes and metacyclic trypomastigotes, whereas Family II is
expressed in trypomastigote mucins and probably in amastigote mucins [45].
One feature of the T. cruzi mucins is that they represent the major acceptors of sialic acid
(SA) by the cell surface trans-sialidase. T. cruzi is unable to synthesize SA, but it expresses the
enzyme TS, which transfers SA from the host to the parasite surface acceptors containing terminal
β-galactosyl residues [49]. This reaction cleaves a SA residue linked in α(2-3) configuration to a
terminal βGalp in the host macromolecule to produce the same linkage on the parasite surface
mucins [50]. Sialylation of the cell surface takes place in all parasite stages except in the amastigote
stage, which lacks TS activity [48]. It is the sialylation of surface molecules in T. cruzi that leads
to the formation of the Ssp-3 epitope [51]. This epitope is found exclusively in the surface of the
infective trypomastigote stage, and it has been demonstrated to be crucial for the recognition and
invasion of mammalian cells as well as diverting the complement cascade [4, 47, 51].
Despite their complexity and heterogeneity, the mucins of T. cruzi can be divided in two
major types: those present in the triatomine bug and those present in the mammalian host. Mucins
in the epimastigote and metacyclic trypomastigote present a double or triple band in the range of
30-50 kDa when ran on a SDS-PAGE, they have an almost identical amino acid composition,
carbohydrate content and structure [45, 47, 49]. These mucins are encoded by the TcSMUG gene
family, which is composed of two groups named S and L that display an average of >80% identity.
TcSMUG S products are the backbone of for the 30/50 kDa mucins, they bind to target cells and
induce a bidireccional Ca2+ response which contributes to host cell invasion. TcSMUG L genes
encode mucin-type glycoconjugates restricted to the epimastigote form and their products are not
acceptors for SA residues. TcSMUG products have features of insect stage apo-mucins, including
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the lack of major sequence variability and the presence of a region rich in Thr in the central domain
[52].
A noticeable difference in the mucin structure between these two insect stages of the
parasite is in the GPI anchor. When the epimastigote transforms into the metacyclic
trypomastigote, the O-linked oligosaccharides and the GPI glycan core remain unchanged, but the
lipid portion of the GPI anchor changes from alkylacylphophatidylinositol to mostly inositol
phosphoceramides [45, 47, 53, 54].
Mucins from the cell-derived trypomastigote form run on SDS-PAGE as a smear with a
wide variety of molecular masses ranging from 60-200 kDa and share the SA-containing epitope
Ssp-3. Trypomastigote mucins (also known as tGPI-mucins) are encoded by the TcMUC gene
family comprising ~800 members, their structure is made of a highly conserved N-terminal signal
peptide, a cleavable C-terminal GPI signal and a Thr-rich region [47, 50, 55]. O-glycans in tGPImucins begin with the addition of αGlcNAc to Thr in the core polypeptide, which may remain
unsubstituted or it can be elongated with carbohydrates, mainly Galp. In the presence of SA donors,
tGPI-mucins become rapidly sialylated by the parasite´s TS as previously mentioned, by linking
SA to βGalp. The addition of SA will give a negative charge to the mucin coat providing protection
to the parasite against human anti-α-galactopyranosyl antibodies [50].
Alternatively, the terminal βGalp displayed by the O-glycans of tGPI-mucins can be
modified by αGalp in the parasite´s secretory pathway. This process provides diversification of the
surface mucins and leads to the presentation of the αGal glycotope (Galα1-3Galβ1-4GlcNAcα),
the main target for lytic antibodies in patients with acute and chronic ChD. Actually, the αGal units
are the structural feature that distinguishes the glycoproteins of the trypomastigote stage [4, 47,
55].
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Interestingly, it has been found that cell-derived trypomastigotes constantly shed
extracellular vesicles from the cell body and the flagellum. These vesicles display a complex cargo
of αGal-containing glycoconjugates along with gp85/TS and MASPs [4, 56]. It is postulated that
they are involved in cell-cell communication or in the modulation of the host immune system in
order to establish infection. In fact, these αGal reactive vesicles are internalized by epithelial cells
and macrophages, the latter activating a TLR2-mediated pathway significantly enhancing cell
invasion [47, 57].
A factor that must be taken into consideration when diagnosing ChD using serological tests
is cross-reactivity. T. cruzi and Leishmania spp. belong to the Trypanosomatidae family and thus
both share many antigens that can cause a strong cross-reaction in serological tests for ChD or
leishmaniasis, reducing the accuracy of diagnosis for both infections [58, 59]. Another important
factor is the geographical distribution of T. cruzi and Leishmania spp., which overlaps in several
countries of South and Central America. Serological tests performed in the city of Oran, Argentina
in patients with symptomatic cutaneous leishmaniasis, determined that 35% of the patients were
also infected with T. cruzi. Additionally, in Brazil and some Central American countries,
Trypanosoma rangeli has been found to infect the same vectors and vertebrate hosts as T. cruzi
[60, 61].
Currently, there is not a single test that has 100% sensitive and 100% specificity, but the
WHO and the Ministry of Health in Brazil agree that two or more tests must concur for a sample
to be determined as positive or negative for ChD [62, 63]. It is possible to diagnose most cases
serologically with a combination of a test with high sensitivity in parallel with a test with high
specificity [64]. Our EpM CL-ELISA has shown to have a high sensitivity for anti-T. cruzi IgG
antibodies utilizing epimastigote whole cell lysates. To assess specificity, and as a confirmatory
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test for the EpM CL-ELISA, we decided to perform a western blot using the trypomastigote stage
of the parasite which gives significantly less false-positive and cross-reactive results [35, 65, 66].
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HYPOTHESIS
We hypothesize that the trypomastigote immunoblot will present protein bands indicating
the presence of anti-T. cruzi IgG antibodies in the EpM CL-ELISA seropositive sera samples.

SPECIFIC AIM
To confirm the seropositive results of the EpM-CL-ELISA in the screening of sera samples
from Chihuahua, Mexico.
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MATERIALS AND METHODS
Parasite culture and antigen preparation
T. cruzi Y-strain Mammalian Tissue Culture-Derived Trypomastigotes (TCT) were
obtained from the supernatant of 7 days old LLC-MK2 cells (American Type Culture Collection,
Manassas, VA, USA) cultured with infected blood from C57black α-Gal knockout mice. LLCMK2 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Corning Inc.
Corning, NY, USA) medium supplemented with 10% fetal bovine serum (Corning Inc. Corning,
NY, USA) and 1% Penicillin/Streptomycin (Thermo Fisher Scientific, Waltham, MA, USA),
incubated at 37°C in a 5% CO2 atmosphere (Napco Series 8000 WJ CO2 Incubator, Thermo Fisher
Scientific, Waltham, MA, USA). To collect the parasites the supernatant was removed from the
tissue culture flaks and centrifuged for 10 minutes at 1500 xg. After centrifugation, the parasite
containing medium was incubated at 37°C for 2 h to allow TCTs to separate from the pellet
containing amastigotes and cell debris. Supernatant was then removed and centrifuged at 3000 xg
for 10 minutes at 4°C, the TCT pellet was washed three times in 1 X phosphate buffer saline (pH
7.4). After the third wash, phosphate buffer saline was removed and the TCT pellet was lysed as
previously described above. The lysate suspension was centrifuged at 12,000 xg for 10 minutes at
4°C and supernatant was stored at -80°C until used.
Electrophoresis and western blot
Proteins from the TCT lysate (1.5 µg/well) were resolved by SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) using 6% acrylamide concentration at 90V for 90 minutes. Western
blot was carried out by transferring the proteins in the polyacrylamide gel into nitrocellulose
membranes (Bio-Rad Laboratories, Inc. Hercules, CA, USA). The blotted membranes were
blocked with 10% bovine serum albumin in Tris buffered saline (20 mM Tris and 150 mM
NaCl)/0.05% Tween 20 at pH 7.4 (10% BSA-TBST) for 16 h at 4°C with constant shaking. The
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membranes were cut in strips and each was individually incubated with the serum to be evaluated;
dilutions were 1:1000 for sera samples and the double negative control (non-infected mice sera),
and 1:2000 for positive control (pool of sera from Barcelona patients being treated with
fexinidazole at day zero, kindly provided by Dr. I. C. Almeida, UTEP) diluted in 10% BSA-TBST
for 2 h at room temperature with constant shaking. Strips were washed three times with TBST for
10 min each, then incubated with anti-human IgG biotinylated (GE Healthcare, Little Chalfont,
Buckinghamshire, United Kingdom) diluted 1:10,000 in 10% BSA-TBST at room temperature for
2 h with constant shaking. Three more washes were carried out and each strip was then incubated
with streptavidin-horseradish peroxidase (Thermo Fisher Scientific, Waltham, MA, USA) diluted
1:10,000 in 10% BSA-TBST at room temperature for 1 h with constant shaking. Another three
washes were performed and the immunoblots were developed by chemiluminescence using
SuperSignal™ West Pico Chemiluminescent Substrate (Thermo Fisher Scientific, Waltham, MA,
USA) following the manufacturer’s instructions.
RESULTS
TCT Y-strain immunoblot
In previous studies, immunoblots using TCT whole cell lysate antigens of T. cruzi Y-strain
have shown a reactivity pattern where IgG of acute-phase rabbit sera identified mainly highmolecular-weight components, while the IgG of chronic-phase rabbit sera reacted mainly to low
molecular weight components [67].
In this immunoblot, we assayed the reactivity of the 13 EpM CL-ELISA seropositive
samples with antigens from a whole cell lysate of the trypomastigote form of T. cruzi Y-strain. We
observed different patterns where 12 samples (Fig. 4, lanes 1-5 and 7-13) present reactivity to
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mainly low molecular weight proteins; and 8 samples (Fig. 4, lanes 6-13) reacted mainly with low
and some high molecular weight proteins, especially one ~260kDa.
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Figure 4. Western blot analysis of EpM CL-ELISA seropositive samples. TCT lysate was
resolved in 6% polyacrylamide gel and then transferred to a nitrocellulose
membrane for Western blot analysis of EpM CL-ELISA seropositive patients.
Positive control: pool of Chagasic patients (1:2000), negative control: naïve mice
sera (1:1000) and patient’s sera (1:1000) used as primary antibodies. Secondary
antibody anti-human IgG (1:10,000) and the horse-radish peroxidase conjugated
streptavidin (1:10,000).
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Data analysis
The results of the TCT Y-strain immunoblot were defined as positive by naked-eye
observation of the bands.
DISCUSSION
There are two types of techniques for the detection of anti-T. cruzi antibodies: conventional
tests which are the widely used IHA, IIF and the ELISA that employ the entire parasite or a
complex of parasitic antigens. The likelihood of the infection being diagnosed is high even when
there are low antibody levels. However, there is the chance of false-positive results due to crossreactions between T. cruzi and Leishmania spp. which may lead to misdiagnosis, especially in
areas where both parasites are endemic [57, 68]. In Mexico, it has been reported that leishmaniasis
is endemic in three regions: Gulf of Mexico, Pacific of Mexico and Central Mexico, where T. cruzi
[13] and different species of Leishmania coexist [69]. On the other hand, nonconventional tests
such as PCR or western blot, are developed with the aim of increasing the specificity of serological
diagnosis and to avoid cross-reactivity with other parasitic diseases [62].
Following the recommendations of the WHO for the diagnosis of ChD, we performed the
EpM CL-ELISA which presented a high sensitivity, with 13 seropositive and 306 seronegative
samples from a total of 314 sera. To confirm the results and to assess the specificity of our EpM
CL-ELISA, we performed an immunoblot using a whole cell lysate of T. cruzi trypomastigotes,
the infective stage in the human host, to reduce false positives and cross-reactivity with other
parasites. All 13 samples tested showed several bands indicating the presence of IgG antibodies
against T. cruzi, corroborating the previous results of the EpM CL-ELISA. It is important to notice
the different patterns described by Umezawa E. S. et. al. [67], where reactivity to mainly low
molecular weight proteins suggests ChD is in the chronic phase, and if reactivity is observed
mainly with high molecular weight proteins, ChD is in the acute phase. In our assay, it is suggested
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the 12 sera samples that reacted mainly with low molecular weight proteins samples (Fig. 4, lanes
1-5 and 7-13) represent infected patients in the chronic-phase of ChD; and one patient that reacted
with a protein ~260 kDa represents a patient in the acute-phase of the disease.
The combination of our EpM CL-ELISA as a high sensitive assay and the TCT immunoblot
as a high specificity and confirmatory assay, represent promising diagnostic tools for the diagnosis
of ChD in South, Central and North America.
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